A detailed history of Ubs Oconnor LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 24,752 shares of KROS stock, worth $445,536. This represents 0.1% of its overall portfolio holdings.

Number of Shares
24,752
Holding current value
$445,536
% of portfolio
0.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.68 - $58.07 $95,822 - $133,502
2,299 Added 10.24%
24,752 $1.44 Million
Q2 2024

Aug 14, 2024

BUY
$44.58 - $66.89 $240,732 - $361,206
5,400 Added 31.67%
22,453 $1.03 Million
Q1 2024

May 15, 2024

BUY
$41.26 - $70.48 $121,345 - $207,281
2,941 Added 20.84%
17,053 $1.13 Million
Q4 2023

Feb 14, 2024

SELL
$27.12 - $41.05 $1.25 Million - $1.9 Million
-46,229 Reduced 76.61%
14,112 $561,000
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $157,850 - $215,100
5,000 Added 9.03%
60,341 $1.92 Million
Q2 2023

Aug 14, 2023

BUY
$37.26 - $51.01 $2.06 Million - $2.82 Million
55,341 New
55,341 $2.22 Billion
Q1 2023

May 15, 2023

BUY
$41.44 - $59.32 $6,879 - $9,847
166 Added 0.37%
45,484 $1.94 Million
Q4 2022

Feb 14, 2023

BUY
$39.45 - $51.77 $473,281 - $621,084
11,997 Added 36.0%
45,318 $0
Q3 2022

Nov 14, 2022

SELL
$27.8 - $40.12 $667,200 - $962,879
-24,000 Reduced 41.87%
33,321 $1.25 Billion
Q2 2022

Aug 12, 2022

BUY
$26.03 - $67.04 $841,315 - $2.17 Million
32,321 Added 129.28%
57,321 $1.58 Million
Q1 2022

May 16, 2022

BUY
$42.12 - $59.36 $1.05 Million - $1.48 Million
25,000 New
25,000 $1.36 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $464M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.